Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease

Clin Ther. 2009 Dec;31(12):2900-4. doi: 10.1016/j.clinthera.2009.12.001.

Abstract

Objective: This letter reports on the effect of enzyme replacement therapy with imiglucerase on bone healing and bone and blood abnormalities in a woman with previously untreated type 1 Gaucher disease (GD).

Methods: The 49-year-old patient had been diagnosed with GD at the age of 28 years and had previously undergone splenectomy. She presented with pseudarthrosis 14 months after sustaining a traumatic fracture of the tibia and fibula. Therapy was begun with imiglucerase 60 U/kg q2wk. The effects of treatment on bone healing were monitored radiographically, and effects on blood and bone marrow biology were monitored by hemograms, myelograms, and hematopoietic and mesenchymal clonogenic assays.

Results: Objective bone healing was observed starting in the third month of imiglucerase treatment. Blood abnormalities normalized and bone marrow parameters improved over the first 9 months, including a decrease in Gaucher cells, an increase in bone marrow CD34+ cell cloning efficiency, and the appearance of mesenchymal progenitors.

Conclusion: This research letter reports the results of hematologic and bone evaluations during enzyme replacement therapy with imiglucerase in a woman with previously untreated type 1 GD who presented with a traumatic fracture.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Accidental Falls
  • Bone Marrow Cells / pathology
  • Enzyme Replacement Therapy*
  • Female
  • Fibula / diagnostic imaging
  • Fibula / injuries*
  • Fracture Fixation, Internal
  • Fracture Healing*
  • Gaucher Disease / blood
  • Gaucher Disease / complications
  • Gaucher Disease / enzymology
  • Gaucher Disease / therapy*
  • Glucosylceramidase / therapeutic use*
  • Hematologic Diseases / blood
  • Hematologic Diseases / enzymology
  • Hematologic Diseases / etiology
  • Hematologic Diseases / therapy*
  • Humans
  • Middle Aged
  • Pseudarthrosis / diagnostic imaging
  • Pseudarthrosis / enzymology
  • Pseudarthrosis / etiology
  • Pseudarthrosis / therapy*
  • Radiography
  • Tibial Fractures / complications
  • Tibial Fractures / diagnostic imaging
  • Tibial Fractures / enzymology
  • Tibial Fractures / therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Glucosylceramidase
  • imiglucerase